科美诊断(688468) - 2025 Q4 - 年度业绩

Financial Performance - Total revenue for 2025 was CNY 332.68 million, a decrease of 23.75% compared to the previous year[2] - Net profit attributable to shareholders was CNY 44.41 million, down 65.05% year-over-year[2] - The net profit excluding non-recurring gains and losses was CNY 28.15 million, a decline of 72.06% from the previous year[2] - Basic earnings per share decreased by 65.63% to CNY 0.11[2] - Total assets at the end of the reporting period were CNY 1,761.59 million, a decrease of 3.85% from the beginning of the period[2] - Shareholders' equity attributable to the parent company was CNY 1,411.39 million, down 0.35%[2] - The financial data presented is preliminary and unaudited, with the final results to be confirmed in the annual report[6] Market Challenges - The company faced pressure on product prices due to the deep implementation of centralized procurement in the in vitro diagnostics industry[4] Strategic Initiatives - The company maintained high R&D investment to enhance core competitiveness despite the decline in revenue[4] - The company aims to continue its innovation-driven development path and strengthen cost management to adapt to industry changes[5]